

Oberoi Realty (OBER IN)

Management
Meet Update

July 02, 2026

Estimate Change | Target | Reco.

Change in Estimates

	Current		Previous	
	FY27E	FY28E	FY27E	FY28E
Rating	Accumulate		Accumulate	
Target Price	1,920		1,820	
Sales (INR mn)	71,088	82,372	70,859	82,860
% Chng.	0.3	(0.6)		
EBITDA (INR mn)	39,920	46,485	39,546	46,517
% Chng.	0.9	(0.1)		
EPS (INR)	79.9	94.2	79.5	94.3
% Chng.	0.5	(0.1)		

Key Data

OEBO.BO | OBER IN

BSE Code	533273
NSE Code	OBEROIRLTY
52-W High / Low	INR 1,940 / INR 1,390
Face Value	10
Sensex / Nifty	76,923 / 24,006
Market Cap	INR 658 bn / \$ 6,910 mn
Shares Outstanding	363.6 mn
3M Avg. Daily Value	INR 918.21 mn

Shareholding Pattern (%)

Promoters	67.70
FIs	15.42
Mutual Funds	12.71
Domestic Institutions	1.87
Public & Others (INR bn)	2.29
Promoter's Pledge	-

Stock Performance (%)

	1M	3M	6M	12M
Absolute	9.7	22.8	6.7	(5.4)
Relative	5.9	16.7	18.2	2.9

Key Financials - Consolidated

Y/e Mar	FY25	FY26	FY27E	FY28E
Sales (INR mn)	52,863	60,091	71,088	82,372
EBITDA (INR mn)	31,031	33,582	39,920	46,485
Margin (%)	58.7	55.9	56.2	56.4
PAT (INR mn)	22,255	25,074	29,085	34,277
EV (INR mn)	689,588	678,394	680,847	674,992
Total Debt (INR mn)	41,501	37,246	37,668	39,821
C&C Eq. (INR mn)	10,030	16,968	14,936	22,945
EPS (INR)	61.2	69.0	80.0	94.3
Gr. (%)	15.6	12.7	16.0	17.9
DPS (INR)	7.0	2.3	10.4	12.0
Yield (%)	0.4	0.1	0.6	0.6
RoE (%)	15.1	14.9	15.3	15.8
RoCE (%)	16.3	15.6	16.8	17.5
EV/Sales (x)	13.0	11.3	9.6	8.2
EV/EBITDA (x)	22.2	20.2	17.1	14.5
PE (x)	29.6	26.2	22.6	19.2
P/BV (x)	4.2	3.7	3.3	2.8

Growth to accelerate

Quick Pointers

- Expect pre-sales growth of ~22% CAGR over FY26-28E
- Strong response anticipated for 360 North project
- BD activities to gather pace

Oberoi Realty Ltd (OBER) saw moderate growth in pre-sales with ~8% CAGR over FY22-26 to INR ~55bn. We foresee ~22% pre-sales CAGR over FY26-28E fueled by successful new launches, rapid inventory absorption from existing projects, and strong demand across the MMR market. We expect strong response for recently launched 360 North project in Gurugram with likely +30-35bn of pre-sales from this project in FY27. Further, we expect annuity income to remain steady at INR13-14bn by FY28E, providing strong cash flow visibility. We retain our 'Accumulate' rating and DCF-derived NAV with SOTP-based TP of INR1,920/share.

Pre-sales to grow ~22% CAGR over FY26-28E: FY26 pre-sales grew a modest 4% YoY to INR55bn due to limited launches. However OBER's FY27-28E pipeline is one of its strongest to date, comprising key launches across Gurugram, Mumbai, Thane and Alibaug. OBER's recent entry into Gurugram provides strong sales visibility in FY27. We expect healthy response to this project with INR30-35bn of pre-sales in FY27. In addition, INR50-60bn of ready-to-move unsold inventory, particularly at 360 West, provides a meaningful near-term pre-sales cushion. Overall, we expect pre-sales to scale to ~INR80bn by FY28E, implying strong CAGR of ~22% over FY26-28E, supported by sustained premium housing demand and progressive monetization of new launches.

Annuity portfolio to accelerate further: OBER's annuity portfolio continues to scale, with leasing income rising at 57% CAGR to INR11.3bn over FY23-26, supported by ~7msf of leasable area across Commerz I-III, Oberoi and Sky City Mall. Commerz III achieved 98% occupancy in Q4FY26, while Sky City Mall reached 72%, with full occupancy targeted by Q4FY27E. As these assets stabilize, we expect annuity income to scale to INR13-14bn by FY28E. Medium-term growth will be supported by ~3msf commercial and retail pipeline, including the Enigma commercial project and the RLDA's BKC commercial development. The management has guided for annuity income to reach INR50bn by FY31/32E end.

BD pipeline: OBER has ramped up BD activities and managed to create a healthy launch pipeline. Recent additions include ~2msf project in Bandra East and multiple redevelopment agreements across premium South Mumbai micro-markets such as Pedder Road, Malabar Hill, Bandra, Worli and Nepean Sea Road, alongside the NCLT-approved Horizon Hotel acquisition. The management indicated that it will continue to aggressively pursue BD activities, which should drive pre-sales and annuity income beyond FY28.

Hospitality portfolio: The Westin hotel in Goregaon with 269 keys enjoys healthy occupancy of 77% and ARR of INR12,445/night (as of FY26). OBER plans to open The Ritz-Carlton at 360 West in FY27E and Marriott Borivali in Q1/Q2FY28E, which would contribute to incremental hospitality revenue. Overall, OBER plans to expand its hospitality portfolio to ~1,100 keys over the next 4–5 years. We expect hospitality income to grow by 40% CAGR over FY26–28E to INR3.6bn by FY28E.

Valuation: We value the residential business at INR272bn (INR750/share), taking into account recent BD activities. The annuity portfolio accounts for INR247bn (INR680/share), assuming 8–8.5% cap rate. For the hospitality segment, operating assets are valued at INR23bn (18x EBITDA on FY28E). Further, we have assumed 30% premium to gross NAV. Thus, we arrive at NAV of INR1,920/ share. We maintain 'Accumulate' rating on the stock.


Exhibit 1: NAV valuation summary

Particulars	NAV (INR mn)	% of total	NAV per share (INR)
Residential	277,169	51%	762
Commercial (Lease)	170,593	31%	469
Retail (Lease)	76,782	14%	211
Hospitality	22,582	4%	62
Gross NAV	547,096	100%	1505
Add: Cash	14,936		41
Less: Gross Debt	-27,231		-75
30% Premium to NAV	164,129		
Net NAV	698,930		1920
Outstanding shares (mn)	363.6		
Target price per share (INR)			1,920

Source: PL


Story in Charts

Exhibit 2: Pre-sales log ~8% CAGR over FY22-26




Source: Company, PL

Exhibit 3: Collections grow 8% CAGR FY22-26




Source: Company, PL

Exhibit 4: Annuity income grows at ~44% CAGR over FY22-26 to INR11bn




Source: Company, PL

Exhibit 5: Hospitality income increases at 29% CAGR over FY22-26




Source: Company, PL

Exhibit 6: Average realization at 10% CAGR over FY23-26



Source: Company, PL

Exhibit 7: Strong OCF generation over FY23-26



Source: Company, PL

Financials

Income Statement (INR mn)

Y/e Mar	FY25	FY26	FY27E	FY28E
Net Revenues	52,863	60,091	71,088	82,372
YoY gr. (%)	17.6	13.7	18.3	15.9
Cost of Goods Sold	18,450	22,650	26,940	31,376
Gross Profit	34,413	37,441	44,148	50,997
Margin (%)	65.1	62.3	62.1	61.9
Employee Cost	1,143	1,347	1,436	1,632
Other Expenses	-	-	-	-
EBITDA	31,031	33,582	39,920	46,485
YoY gr. (%)	28.8	8.2	18.9	16.4
Margin (%)	58.7	55.9	56.2	56.4
Depreciation and Amortization	885	1,308	1,505	1,805
EBIT	30,146	32,273	38,415	44,679
Margin (%)	57.0	53.7	54.0	54.2
Net Interest	2,652	2,406	2,500	2,500
Other Income	1,879	2,952	2,900	3,300
Profit Before Tax	29,373	32,819	38,815	45,479
Margin (%)	55.6	54.6	54.6	55.2
Total Tax	7,194	7,682	9,898	11,370
Effective Tax Rate (%)	24.5	23.4	26.0	25.0
Profit After Tax	22,179	25,137	28,917	34,109
Minority Interest	-	-	-	-
Share Profit from Associate	76	168	168	168
Adjusted PAT	22,255	25,074	29,085	34,277
YoY gr. (%)	15.6	12.7	16.0	17.9
Margin (%)	42.1	41.7	40.9	41.6
Extra Ord. Income / (Exp)	-	-	-	-
Reported PAT	22,255	25,074	29,085	34,277
YoY gr. (%)	15.6	12.7	16.0	17.9
Margin (%)	42.1	41.7	40.9	41.6
Other Comprehensive Income	-	-	-	-
Total Comprehensive Income	22,255	25,074	29,085	34,277
Equity Shares O/s (mn)	364	364	364	364
EPS (INR)	61.2	69.0	80.0	94.3

Source: Company, PL

Balance Sheet (INR mn)

Y/e Mar	FY25	FY26	FY27E	FY28E
Non-Current Assets				
Gross Block	51,776	53,240	67,449	70,030
Tangibles	51,766	53,040	67,250	69,831
Intangibles	11	199	199	199
Acc: Dep / Amortization	4,928	6,236	7,741	9,546
Tangibles	4,928	6,236	7,741	9,546
Intangibles	-	-	-	-
Net Fixed Assets	46,848	47,003	59,708	60,484
Tangibles	46,837	46,804	59,509	60,284
Intangibles	11	199	199	199
Capital Work In Progress	16,044	17,517	22,501	31,052
Goodwill	-	-	-	-
Non-Current Investments	25,353	17,373	17,373	17,373
Net Deferred Tax Assets	1,091	1,439	1,439	1,439
Other Non-Current Assets	6,416	10,170	10,170	10,170
Current Assets				
Investments	-	-	-	-
Inventories	94,465	101,832	110,629	121,727
Trade Receivables	1,127	3,240	1,500	1,500
Cash & Bank Balance	10,030	16,968	14,936	22,945
Other Current Assets	20,728	31,798	35,614	40,956
Total Assets	226,062	251,832	278,362	312,138
Equity				
Equity Share Capital	3,636	3,636	3,636	3,636
Other Equity	153,413	175,580	198,420	228,479
Total Network	157,049	179,216	202,056	232,115
Non-Current Liabilities				
Long Term Borrowings	33,004	28,162	27,231	27,231
Provisions	-	-	-	-
Other Non Current Liabilities	-	-	-	-
Current Liabilities				
ST Debt / Current of LT Debt	8,497	9,083	10,437	12,590
Trade Payables	7,638	6,167	7,918	7,888
Other Current Liabilities	20,966	30,642	32,160	33,753
Total Equity & Liabilities	226,062	251,832	278,362	312,138

Source: Company, PL

Cash Flow (INR mn)

Y/e Mar	FY25	FY26	FY27E	FY28E
PBT	29,373	32,819	38,815	45,479
Add. Depreciation	885	1,308	1,505	1,805
Add. Interest	2,652	2,406	2,500	2,500
Less Financial Other Income	1,879	2,952	2,900	3,300
Add. Other	(2,538)	(2,173)	168	168
Op. Profit before WC Changes	30,371	34,361	42,988	49,952
Net Changes-WC	(2,243)	(12,638)	(6,250)	(12,724)
Direct Tax	(6,503)	(7,925)	(9,898)	(11,370)
Net Cash from Op. Activities	21,626	13,799	26,839	25,858
Capital Expenditures	(6,923)	(7,839)	(19,193)	(11,132)
Interest / Dividend Income	2,565	941	-	-
Others	(19,564)	2,268	-	-
Net Cash from Inv. Activities	(23,923)	(4,631)	(19,193)	(11,132)
Issue of Share Cap. / Premium	-	-	-	-
Debt Changes	8,052	(4,842)	(931)	-
Dividend Paid	(3,636)	(2,909)	(3,796)	(4,218)
Interest Paid	(2,652)	(2,406)	(2,500)	(2,500)
Others	2,891	7,927	-	-
Net Cash from Fin. Activities	4,655	(2,230)	(7,227)	(6,718)
Net Change in Cash	2,358	6,938	419	8,009
Free Cash Flow	14,703	5,959	7,646	14,726

Source: Company, PL

Quarterly Financials (INR mn)

Y/e Mar	Q1FY26	Q2FY26	Q3FY26	Q4FY26
Net Revenues	9,876	17,790	14,926	17,498
YoY gr. (%)	(29.7)	34.8	5.8	52.1
Raw Material Expenses	3,896	6,730	5,503	6,521
Gross Profit	5,979	11,061	9,424	10,977
Margin (%)	60.5	62.2	63.1	62.7
EBITDA	5,203	10,203	8,573	9,603
YoY gr. (%)	(36.2)	25.4	0.1	55.4
Margin (%)	52.7	57.4	57.4	54.9
Depreciation / Depletion	316	334	327	331
EBIT	4,887	9,869	8,246	9,272
Margin (%)	49.5	55.5	55.2	53.0
Net Interest	750	712	674	271
Other Income	864	658	691	739
Profit before Tax	5,002	9,815	8,263	9,740
Margin (%)	50.7	55.2	55.4	55.7
Total Tax	857	2,329	1,899	2,597
Effective Tax Rate (%)	17.1	23.7	23.0	26.7
Profit After Tax	4,145	7,486	6,363	7,143
Minority Interest	68	117	94	(110)
Share Profit from Associate	-	-	-	-
Adjusted PAT	4,213	7,603	6,688	7,033
YoY gr. (%)	(27.9)	29.0	8.1	62.4
Margin (%)	42.7	42.7	44.8	40.2
Extra Ord. Income / (Exp)	-	-	-	-
Reported PAT	4,213	7,603	6,688	7,033
YoY gr. (%)	(27.9)	29.0	8.1	62.4
Margin (%)	42.7	42.7	44.8	40.2
Other Comprehensive Income	-	-	-	-
Total Comprehensive Income	4,213	7,603	6,688	7,033
Avg. Shares O/s (mn)	-	-	-	-
EPS (INR)	-	-	-	-

Source: Company, PL

Key Financial Metrics


Y/e Mar	FY25	FY26	FY27E	FY28E
Per Share (INR)				
EPS	61.2	69.0	80.0	94.3
CEPS	63.6	72.6	84.1	99.2
BVPS	431.9	492.9	555.7	638.4
FCF	40.4	16.4	21.0	40.5
DPS	7.0	2.3	10.4	12.0
Return Ratio (%)				
RoCE	16.3	15.6	16.8	17.5
ROIC	14.0	13.7	14.6	15.4
RoE	15.1	14.9	15.3	15.8
Balance Sheet				
Net Debt : Equity (x)	0.2	0.1	0.1	0.1
Net Working Capital (Days)	607	601	535	511
Valuation (x)				
PER	29.5	26.2	22.6	19.1
P/B	4.1	3.6	3.2	2.8
P/CEPS	28.4	24.9	21.5	18.2
EV/EBITDA	22.2	20.2	17.0	14.5
EV/Sales	13.0	11.2	9.5	8.1
Dividend Yield (%)	0.3	0.1	0.5	0.6
FCFF Yield (%)	2.2	0.9	1.1	2.2
PEG Ratio	1.8	2.0	1.4	1.0

Source: Company, PL

Key Operating Metrics

Y/e Mar	FY25	FY26	FY27E	FY28E
Residential pre-sales	52,592	54,475	74,025	80,113
Leasing income	8,694	12,494	12,147	13,438
Hospitality income	1,919	1,980	2,053	3,580

Source: Company, PL

Price Chart

Recommendation History

No.	Date	Rating	TP (INR)	Share Price (INR)
1	12-May-26	Accumulate	1820	1635
2	09-Apr-26	Accumulate	1820	1641.5
3	16-Jan-26	Accumulate	1820	1647

Analyst Coverage Universe

Sr. No.	Company Name	Rating	TP (INR)	Share Price (INR)
1	Ajanta Pharma	BUY	3400	2898
2	Anthem Biosciences	BUY	850	781
3	Apollo Hospitals Enterprise	BUY	9350	8309
4	Aster DM Healthcare	Buy	800	701
5	Aurobindo Pharma	Hold	1400	1464
6	Brigade Enterprises	Buy	1045	758
7	Cipla	Accumulate	1400	1328
8	Divi's Laboratories	Accumulate	6900	6887
9	Dr. Reddy's Laboratories	Accumulate	1400	1270
10	Eris Lifesciences	BUY	1750	1458
11	Fortis Healthcare	Buy	1120	970
12	Global Health	BUY	1450	1243
13	HealthCare Global Enterprises	BUY	820	650
14	Indoco Remedies	Hold	325	225
15	Ipca Laboratories	BUY	1800	1490
16	J.B. Chemicals & Pharmaceuticals	Buy	2400	2135
17	Jupiter Life Line Hospitals	Buy	1600	1331
18	Krishna Institute of Medical Sciences	Buy	800	717
19	Lupin	Accumulate	2500	2380
20	Max Healthcare Institute	Buy	1175	1023
21	Narayana Hrudayalaya	BUY	2250	1891
22	Oberoi Realty	Accumulate	1820	1635
23	Prestige Estates Projects	Buy	1800	1402
24	Rainbow Children's Medicare	BUY	1700	1327
25	Sun Pharmaceutical Industries	Buy	2070	1845
26	Sunteck Realty	Buy	520	356
27	Torrent Pharmaceuticals	Buy	5000	4573
28	Zydus Lifesciences	Accumulate	1080	1019

PL's Recommendation Nomenclature (Absolute Performance)

BUY	: > 15%
Accumulate	: 5% to 15%
Hold	: +5% to -5%
Reduce	: -5% to -15%
Sell	: < -15%
Not Rated (NR)	: No specific call on the stock
Under Review (UR)	: Rating likely to change shortly

ANALYST CERTIFICATION

Indian Clients

We/I Mr. Param Desai MBA Finance, Ms. Sanketa Kohale MBA Finance Research Analysts, authors and the names subscribed to this report, hereby certify that all of the views expressed in this research report accurately reflect our views about the subject issuer(s) or securities. We also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this report.

US Clients

The research analysts, with respect to each issuer and its securities covered by them in this research report, certify that: All of the views expressed in this research report accurately reflect his or her or their personal views about all of the issuers and their securities; and No part of his or her or their compensation was, is or will be directly related to the specific recommendation or views expressed in this research report.

Prabhudas Lilladher Pvt. Ltd.

Corporate Office: 6th Floor, Tower 2B South Annex, One World Centre, 841, Senapati Bapat Marg, Lower Parel, Mumbai - 400013

Registered Office: 3rd Floor, Sadhana House, 570, P. B. Marg, Worli, Mumbai-400 018

Tel: (91 22) 6632 2222 Fax: (91 22) 6632 2209

www.plindia.com

DISCLAIMER

Indian Clients

Prabhudas Lilladher Pvt. Ltd, Mumbai, India (hereinafter referred to as "PL") is engaged in the business of Stock Broking, Portfolio Manager, Depository Participant and distribution for third party financial products. PL is a subsidiary of Prabhudas Lilladher Advisory Services Pvt Ltd, which has its various subsidiaries engaged in business of commodity broking, investment banking, financial services (margin funding) and distribution of third party financial/other products, details in respect of which are available at www.plindia.com.

This document has been prepared by the Research Division of PL and is meant for use by the recipient only as information and is not for circulation. This document is not to be reported or copied or made available to others without prior permission of PL. It should not be considered or taken as an offer to sell or a solicitation to buy or sell any security.

The information contained in this report has been obtained from sources that are considered to be reliable. However, PL has not independently verified the accuracy or completeness of the same. Neither PL nor any of its affiliates, its directors or its employees accepts any responsibility of whatsoever nature for the information, statements and opinion given, made available or expressed herein or for any omission therein.

Recipients of this report should be aware that past performance is not necessarily a guide to future performance and value of investments can go down as well. The suitability or otherwise of any investments will depend upon the recipients particular circumstances and, in case of doubt, advice should be sought from an independent expert/advisor.

Either PL or its affiliates or its directors or its employees or its representatives or its clients or their relatives may have position(s), make market, act as principal or engage in transactions of securities of companies referred to in this report and they may have used the research material prior to publication.

PL may from time to time solicit or perform investment banking or other services for any company mentioned in this document.

PL is a registered with SEBI under the SEBI (Research Analysts) Regulation, 2014 and having registration number INH000000271.

PL submits that no material disciplinary action has been taken on us by any Regulatory Authority impacting Equity Research Analysis activities.

PL or its research analysts or its associates or his relatives do not have any financial interest in the subject company.

PL or its research analysts or its associates or his relatives do not have any material conflict of interest at the time of publication of the research report.

PL or its associates might have received compensation from the subject company in the past twelve months.

PL or its research analysts or its associates or his relatives do not have actual/beneficial ownership of one per cent or more securities of the subject company at the end of the month immediately preceding the date of publication of the research report.

PL or its associates might have managed or co-managed public offering of securities for the subject company in the past twelve months or mandated by the subject company for any other assignment in the past twelve months.

PL or its associates might have received any compensation for investment banking or merchant banking or brokerage services from the subject company in the past twelve months.

PL or its associates might have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past twelve months

PL or its associates might have received any compensation or other benefits from the subject company or third party in connection with the research report.

PL encourages independence in research report preparation and strives to minimize conflict in preparation of research report.

PL or its analysts did not receive any compensation or other benefits from the subject Company or third party in connection with the preparation of the research report.

PL or its Research Analysts do not have any material conflict of interest at the time of publication of this report.

It is confirmed that Mr. Param Desai MBA Finance, Ms. Sanketa Kohale MBA Finance Research Analysts of this report have not received any compensation from the companies mentioned in the report in the preceding twelve months. Compensation of our Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions.

The Research analysts for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

The research analysts for this report has not served as an officer, director or employee of the subject company PL or its research analysts have not engaged in market making activity for the subject company

Our sales people, traders, and other professionals or affiliates may provide oral or written market commentary or trading strategies to our clients that reflect opinions that are contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest.

PL and its associates, their directors and employees may (a) from time to time, have a long or short position in, and buy or sell the securities of the subject company or (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the subject company or act as an advisor or lender/borrower to the subject company or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions.

Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors

US Clients

This research report is a product of Prabhudas Lilladher Pvt. Ltd., which is the employer of the research analyst(s) who has prepared the research report. The research analyst(s) preparing the research report is/are resident outside the United States (U.S.) and are not associated persons of any U.S. regulated broker-dealer and therefore the analyst(s) is/are not subject to supervision by a U.S. broker-dealer, and is/are not required to satisfy the regulatory licensing requirements of FINRA or required to otherwise comply with U.S. rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities held by a research analyst account.

This report is intended for distribution by Prabhudas Lilladher Pvt. Ltd. only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the U.S. Securities and Exchange Act, 1934 (the Exchange Act) and interpretations thereof by U.S. Securities and Exchange Commission (SEC) in reliance on Rule 15a 6(a)(2). If the recipient of this report is not a Major Institutional Investor as specified above, then it should not act upon this report and return the same to the sender. Further, this report may not be copied, duplicated and/or transmitted onward to any U.S. person, which is not the Major Institutional Investor.

In reliance on the exemption from registration provided by Rule 15a-6 of the Exchange Act and interpretations thereof by the SEC in order to conduct certain business with Major Institutional Investors, Prabhudas Lilladher Pvt. Ltd. has entered into an agreement with a U.S. registered broker-dealer, Marco Polo Securities Inc. ("Marco Polo").

Transactions in securities discussed in this research report should be effected through Marco Polo or another U.S. registered broker dealer.